FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302773352> ?p ?o ?g. }

• W4302773352 endingPage "1462" @default.
• W4302773352 startingPage "1449" @default.
• W4302773352 abstract "Clinical trials have produced promising results for disease-modifying therapies (DMTs) for Alzheimer's disease (AD); however, the evidence on their potential cost-effectiveness is limited. This study assesses the cost-effectiveness of a hypothetical DMT with a limited treatment duration in AD.We developed a Markov state-transition model to estimate the cost-effectiveness of a hypothetical DMT plus best supportive care (BSC) versus BSC alone among Americans living with mild cognitive impairment (MCI) due to AD or mild AD. AD states included MCI due to AD, mild AD, moderate AD, severe AD, and death. A hypothetical DMT was assumed to confer a 30% reduction in progression from MCI and mild AD. The base case annual drug acquisition cost was assumed to be $56,000. Other medical and indirect costs were obtained from published literature or list prices. Utilities for patients and caregivers were obtained from the published literature and varied by AD state and care setting (community care or long-term care). We considered 3 DMT treatment strategies: (1) treatment administered until patients reached severe AD (continuous strategy), (2) treatment administered for a maximum duration of 18 months or when patients reached severe AD (fixed-duration strategy), and (3) 40% of patients discontinuing treatment at 6 months because of amyloid plaque clearance and the remaining patients continuing treatment until 18 months or until they reached severe AD (test-and-discontinue strategy). Incremental cost-effectiveness ratios (ICERs) were calculated as the incremental cost per quality-adjusted life-year (QALY) gained.From the health care sector perspective, continuous treatment with a hypothetical DMT versus BSC resulted in an ICER of $612,354 per QALY gained. The ICER decreased to $157,288 per QALY gained in the fixed-duration strategy, driven by large reductions in treatment costs. With 40% of patients discontinuing treatment at 6 months (test-and-discontinue strategy), the ICER was $125,631 per QALY gained. In sensitivity and scenario analyses, the ICER was the most sensitive to changes in treatment efficacy, treatment cost, and the initial population AD state distribution. From the modified societal perspective, ICERs were 6.3%, 20.4%, and 25.1% lower than those from the health care sector perspective for the continuous, fixed-duration, and test-and-discontinue strategies, respectively.Under a set of assumptions for annual treatment costs and the magnitude and duration of treatment efficacy, DMTs used for a limited duration may deliver value consistent with accepted US cost-effectiveness thresholds." @default.
• W4302773352 created "2022-10-07" @default.
• W4302773352 creator A5001431413 @default.
• W4302773352 creator A5007379923 @default.
• W4302773352 creator A5013337549 @default.
• W4302773352 creator A5015927873 @default.
• W4302773352 creator A5019055956 @default.
• W4302773352 creator A5027402674 @default.
• W4302773352 creator A5039849825 @default.
• W4302773352 creator A5058526962 @default.
• W4302773352 creator A5060938706 @default.
• W4302773352 creator A5091330723 @default.
• W4302773352 date "2022-11-01" @default.
• W4302773352 modified "2023-10-13" @default.
• W4302773352 title "Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease" @default.
• W4302773352 cites W2031772714 @default.
• W4302773352 cites W2038593189 @default.
• W4302773352 cites W2039585634 @default.
• W4302773352 cites W2049570029 @default.
• W4302773352 cites W2058056848 @default.
• W4302773352 cites W2060252294 @default.
• W4302773352 cites W2111769573 @default.
• W4302773352 cites W2114983566 @default.
• W4302773352 cites W2119084244 @default.
• W4302773352 cites W2122843800 @default.
• W4302773352 cites W2138904731 @default.
• W4302773352 cites W2318933458 @default.
• W4302773352 cites W2518059812 @default.
• W4302773352 cites W2519603001 @default.
• W4302773352 cites W2788249140 @default.
• W4302773352 cites W2906765081 @default.
• W4302773352 cites W2923168235 @default.
• W4302773352 cites W2930696305 @default.
• W4302773352 cites W3014253589 @default.
• W4302773352 cites W3112231948 @default.
• W4302773352 cites W3118389339 @default.
• W4302773352 cites W3137826907 @default.
• W4302773352 cites W3152692563 @default.
• W4302773352 cites W3163695789 @default.
• W4302773352 cites W3195630219 @default.
• W4302773352 cites W3205834137 @default.
• W4302773352 cites W3210814279 @default.
• W4302773352 cites W3210916380 @default.
• W4302773352 cites W4205869346 @default.
• W4302773352 cites W4206817121 @default.
• W4302773352 cites W4211104519 @default.
• W4302773352 cites W4211238543 @default.
• W4302773352 cites W4221124351 @default.
• W4302773352 doi "https://doi.org/10.1016/j.clinthera.2022.09.008" @default.
• W4302773352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36210219" @default.
• W4302773352 hasPublicationYear "2022" @default.
• W4302773352 type Work @default.
• W4302773352 citedByCount "3" @default.
• W4302773352 countsByYear W43027733522023 @default.
• W4302773352 crossrefType "journal-article" @default.
• W4302773352 hasAuthorship W4302773352A5001431413 @default.
• W4302773352 hasAuthorship W4302773352A5007379923 @default.
• W4302773352 hasAuthorship W4302773352A5013337549 @default.
• W4302773352 hasAuthorship W4302773352A5015927873 @default.
• W4302773352 hasAuthorship W4302773352A5019055956 @default.
• W4302773352 hasAuthorship W4302773352A5027402674 @default.
• W4302773352 hasAuthorship W4302773352A5039849825 @default.
• W4302773352 hasAuthorship W4302773352A5058526962 @default.
• W4302773352 hasAuthorship W4302773352A5060938706 @default.
• W4302773352 hasAuthorship W4302773352A5091330723 @default.
• W4302773352 hasBestOaLocation W43027733521 @default.
• W4302773352 hasConcept C112930515 @default.
• W4302773352 hasConcept C126322002 @default.
• W4302773352 hasConcept C159110408 @default.
• W4302773352 hasConcept C177713679 @default.
• W4302773352 hasConcept C187212893 @default.
• W4302773352 hasConcept C2779134260 @default.
• W4302773352 hasConcept C2779951463 @default.
• W4302773352 hasConcept C3019080777 @default.
• W4302773352 hasConcept C64332521 @default.
• W4302773352 hasConcept C71924100 @default.
• W4302773352 hasConceptScore W4302773352C112930515 @default.
• W4302773352 hasConceptScore W4302773352C126322002 @default.
• W4302773352 hasConceptScore W4302773352C159110408 @default.
• W4302773352 hasConceptScore W4302773352C177713679 @default.
• W4302773352 hasConceptScore W4302773352C187212893 @default.
• W4302773352 hasConceptScore W4302773352C2779134260 @default.
• W4302773352 hasConceptScore W4302773352C2779951463 @default.
• W4302773352 hasConceptScore W4302773352C3019080777 @default.
• W4302773352 hasConceptScore W4302773352C64332521 @default.
• W4302773352 hasConceptScore W4302773352C71924100 @default.
• W4302773352 hasFunder F4320307758 @default.
• W4302773352 hasIssue "11" @default.
• W4302773352 hasLocation W43027733521 @default.
• W4302773352 hasLocation W43027733522 @default.
• W4302773352 hasOpenAccess W4302773352 @default.
• W4302773352 hasPrimaryLocation W43027733521 @default.
• W4302773352 hasRelatedWork W1839838842 @default.
• W4302773352 hasRelatedWork W192322703 @default.
• W4302773352 hasRelatedWork W1983984088 @default.
• W4302773352 hasRelatedWork W2000702096 @default.
• W4302773352 hasRelatedWork W2012275752 @default.
• W4302773352 hasRelatedWork W2076985335 @default.

• next